140 related articles for article (PubMed ID: 37143124)
1. Echinomycin as a promising therapeutic agent against KSHV-related malignancies.
Chen J; Lin Z; Song J; Plaisance-Bonstaff K; James J; Mu S; Post SR; Dai L; Qin Z
J Hematol Oncol; 2023 May; 16(1):48. PubMed ID: 37143124
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Paul AG; Chandran B; Sharma-Walia N
Transl Res; 2013 Aug; 162(2):77-92. PubMed ID: 23567332
[TBL] [Abstract][Full Text] [Related]
4. ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.
Wood JJ; Boyne JR; Paulus C; Jackson BR; Nevels MM; Whitehouse A; Hughes DJ
J Virol; 2016 Oct; 90(20):9543-55. PubMed ID: 27512077
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
6. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
7. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
[TBL] [Abstract][Full Text] [Related]
8. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
Watanabe T; Fujimuro M
Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
[TBL] [Abstract][Full Text] [Related]
9. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
J Virol; 2017 May; 91(10):. PubMed ID: 28275189
[TBL] [Abstract][Full Text] [Related]
10. The Expression and Nuclear Retention Element of Polyadenylated Nuclear RNA Is Not Required for Productive Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.
Gutierrez IV; Dayton J; Harger S; Rossetto CC
J Virol; 2021 Jun; 95(13):e0009621. PubMed ID: 33853955
[TBL] [Abstract][Full Text] [Related]
11. NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.
Hughes DJ; Wood JJ; Jackson BR; Baquero-Pérez B; Whitehouse A
PLoS Pathog; 2015 Mar; 11(3):e1004771. PubMed ID: 25794275
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-κB-Signaling Axis.
Yan Q; Zhao R; Shen C; Wang F; Li W; Gao SJ; Lu C
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976660
[TBL] [Abstract][Full Text] [Related]
13. FoxO1 Suppresses Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication and Controls Viral Latency.
Gao R; Li T; Tan B; Ramos da Silva S; Jung JU; Feng P; Gao SJ
J Virol; 2019 Feb; 93(3):. PubMed ID: 30404794
[TBL] [Abstract][Full Text] [Related]
14. Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis.
Mesri EA; Cavallin LE; Ashlock BM; Leung HJ; Ma Q; Goldschmidt-Clermont PJ
Immunol Res; 2013 Dec; 57(1-3):159-65. PubMed ID: 24203444
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin 6 Attenuates Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Suppressing Ori-Lyt Activity and Expression of RTA.
Hu M; Armstrong N; Seto E; Li W; Zhu F; Wang PC; Tang Q
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651359
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase.
Cheng F; He M; Jung JU; Lu C; Gao SJ
J Virol; 2016 Jul; 90(14):6515-6525. PubMed ID: 27147746
[TBL] [Abstract][Full Text] [Related]
17. Regulation of KSHV Latency and Lytic Reactivation.
Broussard G; Damania B
Viruses; 2020 Sep; 12(9):. PubMed ID: 32957532
[TBL] [Abstract][Full Text] [Related]
18. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
[TBL] [Abstract][Full Text] [Related]
19. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H
Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
[TBL] [Abstract][Full Text] [Related]
20. Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use.
Beauclair G; Naimo E; Dubich T; Rückert J; Koch S; Dhingra A; Wirth D; Schulz TF
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
